Skip to main content
Bimekizumab (BKZ) in AxSpA to Wk52 ◦ sustained efficacy ◦ suppression of inflammation ◦ improvements in function and quality of life ◦ no new safety signals were observed ◦ consistent with the safety profileWk24 data Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Dr. Antoni Chan
14-11-2022
×